Myelodysplastic syndromes - An overview for the practitioner;Myelodysplastische syndrome - Gar nicht so selten

Therapeutische Umschau

Volumn 61, Issue 2, 2004, Pages 117-124

  Solenthaler, Max ^a   Tobler, A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; C REACTIVE PROTEIN; COLECALCIFEROL; CREATININE; CYANOCOBALAMIN; CYCLOSPORIN A; CYTARABINE; FOLIC ACID; GAMMA GLUTAMYLTRANSFERASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HAPTOGLOBIN; HYDROXYUREA; LACTATE DEHYDROGENASE; PREDNISONE; PYRIDOXINE; RECOMBINANT ERYTHROPOIETIN; THYMOCYTE ANTIBODY; TRANEXAMIC ACID;

CLINICAL EXAMINATION; DISEASE CLASSIFICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MYELODYSPLASTIC SYNDROME; PROGNOSIS; REVIEW;

EID: 1342283172     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.61.2.117     Document Type: Review

References (19)

1. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992; 82: 358-67.
2. Passmore SJ, Chessells JM, Kempski H, Hann IM, Brownbill PA, Stiller CA. Paediatric myelodysplastic syndromes andjuvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol 2003; 121: 758-67.
3. Aul C, Gattermann N, Schneider W. Epidemiological and etiological aspects of myelodysplastic syndromes. Leuk Lymphoma 1995; 16: 247-62.
4. Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am 1993; 7: 81-107.
5. Rigolin GM, Cuneo A, Roberti MG et al. Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinicobiological findings. Br J Haematol 1998; 103: 189-97.
6. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-99.
7. Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds.): Word Health Organization Classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press: Lyon, 2001.
8. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-88. Erratum in Blood 1998; 91: 1100.
9. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-88. Erratum in Blood 1998; 91: 1100.
10. Bowen D, Culligan D, Jowitt S et al. UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120: 187-200.
11. Alessandrino EP, Amadori S, Barosi G et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica. 2002; 87: 1286-306.
12. Jensen PD, Heickendorff L, Pedersen B et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional overload. Br J Haematol 1996; 94: 288-99.
13. Molldrem JJ, Leifer E, Bahceci E et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137: 156-63.
14. Jonasova A, Neuwirtova R, Cermak J et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100: 304-9.
15. Raza A, Meyer P, Dutt D et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958-65.
16. Sierra J, Perez WS, Rozman C et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997-2004.
17. de Witte T, Hermans J, Vossen J et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 620-30.
18. Oosterveld M, Suciu S, Verhoef G et al. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia. 2003; 17: 859-68.
19. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-40.